首页> 外文OA文献 >Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
【2h】

Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer

机译:活化的肿瘤浸润性CD4 +调节性T细胞抑制原发性或转移性肝癌患者的抗肿瘤免疫力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The mechanisms that enable liver cancer to escape elimination by the immune system remain unclear, but their elucidation may provide novel therapeutic interventions. We investigated the influence of tumor-infiltrating regulatory T cells on tumor-specific T cell responses in patients with liver cancer, using ex vivo isolated cells from individuals with hepatocellular carcinoma (HCC) or liver metastases from colorectal cancer (LM-CRC). Here we report that in both HCC and LM-CRC, CD4+CD25+Foxp3+ regulatory T cells (Tregs) accumulate in the tumor milieu and are potent suppressors of autologous tumor-specific T cell responses. Especially in LM-CRC, where Treg accumulation is more prominent, there is good evidence for local proliferation of Tregs at the cancer site. We show that tumor Tregs up-regulate the expression of glucocorticoid-induced tumor necrosis factor receptor (GITR) compared with Tregs in tumor-free liver tissue and blood. Importantly, treatment with soluble GITR ligand (GITRL) induces a decrease in the suppression mediated by the activated tumor-infiltrating Tregs and restores the proliferative capacity and cytokine production of CD4+CD25- T cells. Our results show that tumor-associated Tregs are critical for immune evasion in liver cancer, and we propose that GITRL constitutes a rational treatment for this disease
机译:尚不清楚使肝癌能够通过免疫系统消除的机制,但其阐明可能会提供新颖的治疗干预措施。我们使用肝细胞癌(HCC)或结直肠癌(LM-CRC)个体的离体分离细胞,研究了肝癌患者中肿瘤浸润性调节性T细胞对肿瘤特异性T细胞反应的影响。在这里,我们报告在肝癌和LM-CRC中,CD4 + CD25 + Foxp3 +调节性T细胞(Tregs)积累在肿瘤环境中,并且是自体肿瘤特异性T细胞应答的有效抑制剂。尤其是在Treg积累更为突出的LM-CRC中,有充分的证据表明Tregs在癌症部位局部增殖。我们显示,与无肿瘤肝组织和血液中的Treg相比,肿瘤Treg上调了糖皮质激素诱导的肿瘤坏死因子受体(GITR)的表达。重要的是,用可溶性GITR配体(GITRL)治疗诱导了由激活的肿瘤浸润Treg介导的抑制作用的降低,并恢复了CD4 + CD25-T细胞的增殖能力和细胞因子产生。我们的结果表明,与肿瘤相关的Treg对肝癌的免疫逃逸至关重要,我们建议GITRL构成对该疾病的合理治疗

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号